 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
VILDAGLIPTIN (LAF 237): A DIPEPTIDYL PEPTIDASE IV INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Susan Cornell
To request full article click here.
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy and safety studies, adverse effects, drug interactions, dosage, and administration of vildagliptin (LAF 237), a dipeptidyl peptidase IV (DPP-4) inhibitor in Phase III development for the treatment of type 2 diabetes mellitus.
DATA SOURCES: Information was obtained from MEDLINE searches of the English-language literature
(1990–September 2005). Search terms included vildagliptin, LAF 237, DPP-IV inhibitor, DPP-4 inhibitor, and
GLP-1 agonist.
STUDY SELECTION AND DATA EXTRACTION: Available literature reviewed included abstracts, clinical trials with
human and animal data, and review articles.
DATA SYNTHESIS : Vildagliptin is a potent and highly selective DPP-4 inhibitor. This novel treatment modality enhances the activity of incretin hormones through inhibition of the enzyme responsible for their degradation.
CONCLUSIONS: Vildagliptin demonstrates good tolerability with minimal adverse effects and can effectively improve metabolic control of glucose through an array of mechanisms.
J Pharm Technol 2006;22:105-9.
ACPE Universal Program Number: 407-000-06-052-H01
To request full article click here.
|
|
|
||
|
